Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease.</li><li> The company announced its 1Q results that illustrate the company is on the verge of potentially transformational year.</li></ul>

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company announced its 1Q results that illustrate the company is on the verge of potentially transformational year.

<ul><li>Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease.</li><li> The company announced that it had a positive meeting with the FDA regarding the testing of Lomecel-B for the treatment of Alzheimer's.</li><li>The end result is the testing and approval process could be accelerated.</li></ul>

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company announced that it had a positive meeting with the FDA regarding the testing of Lomecel-B for the treatment of Alzheimer's.The end result is the testing and approval process could be accelerated.

LGVN: Alzheimer's Treatment Gets Positive News from FDA

<ul><li>Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease.</li><li> The company announced improved revenue and reduced costs in 2024 results.</li><li>Additionally, the company confirmed it has enough cash on hand to last through 2025 and that testing may be accelerated.</li></ul>

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company announced improved revenue and reduced costs in 2024 results.Additionally, the company confirmed it has enough cash on hand to last through 2025 and that testing may be accelerated.

<ul><li>Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease.</li><li> The company announced improved revenue and reduced costs in its 3Q results.</li><li>Additionally, the company confirmed it has enough cash on hand to last through 2025.</li></ul>

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company announced improved revenue and reduced costs in its 3Q results.Additionally, the company confirmed it has enough cash on hand to last through 2025.

LGVN: Positive Test Results Highlight Quarterly Results

United States

Longeveron Inc. operates as a clinical stage biotechnology company. The Company focuses on developing cellular therapies for specific aging-related and life-threatening conditions. Longeveron serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Longeveron (LGVN US)

LGVN: Setting Up for a Pivotal Year

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...

Zacks Small Cap Research

LGVN: Alzheimer's Treatment Gets Positive News from FDA

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...

Zacks Small Cap Research

LGVN: Great Position for Pivotal Year

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...

Zacks Small Cap Research

LGVN: Great Position for Pivotal Year

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...

Zacks Small Cap Research

LGVN: Positive Test Results Highlight Quarterly Results

Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)